Quarterly report (Form 10-Q)
Caris Life Sciences 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
Also during the second quarter of 2026, we launched Caris MI Clarity, our first commercially available digital, AI/ML-based prognostic solution, which applies computational pathology and machine learning to digitized hematoxylin and eosin whole-slide images together with clinical inputs - without requiring additional genomic sequencing - to assess both early and late distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer.